Skip to content

A randomized controlled trial of continuous nitroglycerine Infusion with or without a preceding nitroglycerine bolus dose in older patients with acute heart failure.

A randomized controlled trial of continuous nitroglycerine Infusion with or without a preceding nitroglycerine bolus dose in older patients with acute heart failure.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230517007
Enrollment
186
Registered
2023-05-17
Start date
2023-07-07
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nitroglycerine bolus dose and follow by in fusion in emergency department older adults with hypertensive heart failure. Nitroglycerine, older adults, hypertension, heart failure

Interventions

Nitroglycerine 1 mg IV bolus and follow by 0.5 ug/kg/min and record the blood pressure from the beginning until 60 minutes. ,Nitroglycerine 0.5 ug/kg/min iv contineous drip and record the blood press
Active Comparator Drug,Active Comparator Drug
Nitroglycerine 1 mg IV bolus and follow by 0.5 ug/kg/min,Nitroglycerine 0.5 ug/kg/min and record the blood pressure from the beginning until 60 minutes.

Sponsors

Navamindradhiraj University Research Fund
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Patients over 65 years of age who come to the emergency room of Vajira Hospital 2. The patient was diagnosed with acute heart failure. 3. The patient has a systolic blood pressure greater than 140 mm Hg.

Exclusion criteria

Exclusion criteria: 1. Have a history of allergy to nitroglycerin 2. Brain accident 3. Severe sepsis (SOFA score >=2, lactate >4, and there is evidence of a source of infection contributing to the symptoms that brought the patient to the emergency room). 4. Liver failure or chronic cirrhosis Stage 3-4 (decompensated liver cirrhosis) 5. Chronic renal failure or end-stage renal disease with a glomerular filtration rate (GFR) of less than 15 ml/min/1.73 m 6. ST elevation (STEMI) or right ventricular ischemia (RV infarction). 7. Having a history of drug use phosphodiesterase type 5 (PDE-5) inhibitors, including sildenafil, tadalafil, vardenafil, within 48 hours 8. Having a history of high intracranial pressure such as brain tumors, cerebral hemorrhage and assessed from other associated symptoms, including severe headache, Blurred vision, double vision, convulsions, depression, loss of consciousness, nausea, vomiting, sudden weakness of one limb. 9. Have a history of hypertrophic cardiomyopathy, restrictive cardiomyopathy 10. Have cardiac temponade 11. Chronic pericarditis (constrictive pericarditis) 12. Weighing less than 40 kilograms or more than 100 kilograms

Design outcomes

Primary

MeasureTime frame
Time to first systolic blood pressure less than 140 mmHg 1 hour after received nitroglycerine Blood pressure measurement using Philips - IntelliVue MX400 every 5 minutes until 60 minutes,Delta change of systolic blood pressure 1 hour after received nitroglycerine Blood pressure measurement using Philips - IntelliVue MX400

Secondary

MeasureTime frame
Accumulation dose of nitroglycerine 1 hour microgram,ICU admission 24 hours rate of ICU admission ,Mortality 30 days rate of mortality ,Intubation 24 hours Intubation rate

Countries

Thailand

Contacts

Public ContactJiraporn Srion

Vajira Hospital, Navamindradhiraj University

jirapon@nmu.ac.th0896840010

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026